SF3B1 and cancer: Furthermore, cancers can harbor recurrent mutations in splicing factors (Dvinge et al., 2016), including gain-of-function mutations in SF3B1 (Ellis et al., 2012; Harbour et al., 2013; Imielinski et al., 2012; Papaemmanuil et al., 2011; Wang et al., 2011; Yoshida et al., 2011) that can sensitize cells to spliceosome modulatory drugs (Obeng et al., 2016).